HDFC Pharma and Healthcare Fund
Ticker: mf12911
Decent
68/100
☆ Add to Watchlist
More Options
L
LIC MF Banking & PSU Fund
The LIC MF Banking & PSU Fund shows decent potential with moderate risks. While it operates in a future-ready sector, challenges in profitability and valuation metrics warrant caution.
View details
A
Axis Nifty 100 Index Fund
The Axis Nifty 100 Index Fund is a decent investment option with a diversified portfolio and consistent growth, but investors should be cautious of market volatility.
View details
B
Bandhan Large Cap Fund
The fund shows potential but has several risks that could impact performance.
View details
H
HSBC CRISIL IBX 50:50 Gilt Plus SDL Apr 2028 Index Fund
The fund shows several weaknesses in growth potential and market sentiment, making it a risky investment.
View details
A
Axis Strategic Bond Fund
The Axis Strategic Bond Fund shows decent potential but faces challenges in profitability and growth consistency.
View details
K
Kotak Special Opportunities Fund
The Kotak Special Opportunities Fund shows decent potential with consistent growth and profitability metrics, but caution is advised due to execution risks and valuation concerns.
View details
F
Franklin India Technology Fund
The fund shows decent potential with consistent growth, but faces challenges in valuation and execution risks.
View details
M
Mirae Asset Balanced Advantage Fund
The Mirae Asset Balanced Advantage Fund shows decent potential with a balanced approach to growth and risk management.
View details
O
Old Bridge Focused Fund
The fund shows potential but faces challenges in growth consistency and profitability metrics.
View details
K
Kotak Multi Asset Omni FOF
The Kotak Multi Asset Omni FOF shows decent potential with a balanced approach to growth and risk management, making it a reasonable investment option.
View details
I
ICICI Pru PSU Equity Fund
The ICICI Pru PSU Equity Fund shows decent potential but faces challenges in profitability and valuation. Investors should be cautious.
View details
N
Nippon India Gilt Fund-DMDO
The Nippon India Gilt Fund-DMDO shows decent potential but faces challenges in profitability and valuation metrics.
View details
N
Nippon India Gilt Fund
The Nippon India Gilt Fund shows decent potential but faces challenges in profitability and liquidity. Investors should be cautious.
View details
I
ICICI Pru BSE Sensex Index Fund
The ICICI Pru BSE Sensex Index Fund presents a decent investment opportunity, reflecting the overall market performance with a balanced risk profile.
View details
M
Mirae Asset Low Duration Fund
The fund shows moderate potential but faces challenges in profitability and growth drivers.
View details
N
Nippon India Nifty Midcap 150 Index Fund
The Nippon India Nifty Midcap 150 Index Fund shows potential for growth but carries certain risks that investors should consider.
View details
Business Overview
HDFC Pharma and Healthcare Fund is a specialized mutual fund designed to invest in the dynamic pharmaceutical and healthcare sectors. Ideal for investors seeking long-term growth through exposure to India's booming healthcare industry, this fund focuses on companies that are poised for significant expansion. With a robust portfolio and experienced management, it aims to deliver attractive returns while mitigating risks associated with sector volatility. This fund is perfect for those looking to diversify their investment in a crucial and resilient market.
- Focuses on pharmaceutical and healthcare sectors
- Ideal for long-term growth investors
- Managed by experienced professionals
- Diversifies investment in a resilient market
- Targets companies with significant growth potential
Investment Thesis
HDFC Pharma and Healthcare Fund stands out due to its strong promoter credibility, robust growth in digital healthcare services, and attractive valuation compared to peers. This combination positions the fund as a compelling investment opportunity in the rapidly evolving healthcare sector.
- Strong backing from HDFC Group, ensuring credibility and stability.
- Significant growth potential in digital healthcare services post-pandemic.
- Valuation metrics indicate attractive entry points compared to industry peers.
- Focus on innovation and technology in healthcare enhances long-term prospects.
- Diversified portfolio reduces risk while maximizing returns.
Opportunity vs Risk
Opportunities
- Growing healthcare sector in India
- Increased demand for pharmaceuticals
- Government support for healthcare initiatives
- Potential for high returns
- Diversification in healthcare investments
Risks ⚠️
- Regulatory changes affecting pharma
- Competition from global players
- Market volatility impacting returns
- Dependency on domestic sales
- Economic downturns affecting healthcare spending
Peer Perspective
HDFC Pharma and Healthcare Fund trades at a slight premium to peers like SBI Healthcare Opportunities Fund and ICICI Prudential Pharma Fund. A sustained improvement in margin stability could trigger a rerating.
📊 Stock Investment Checklist (100 Points)
HDFC Pharma and Healthcare Fund • Updated: 2025-09-29 14:44:15
-
10BusinessHighPharma sector is future-ready with strong growth potential.
-
10GrowthHighConsistent revenue and profit growth observed over the past few years.
-
10ProfitabilityHighROE and ROCE are above industry averages, indicating good profitability.
-
8ValuationHighValuation metrics are reasonable compared to peers.
-
7BalanceHighStrong balance sheet with manageable debt levels.
-
6GovernanceGoodPromoter holding is stable, but some concerns on disclosures.
-
5DriversGoodGrowth drivers are present, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The HDFC Pharma and Healthcare Fund shows decent potential with a strong focus on growth and profitability, though some risks and governance concerns exist.